BXN Signs Exclusive $7m Manufacturing and Supply Agreement
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 3 Apr 2025, 8:32 a.m. |
| Price Sensitive | Yes |
Bioxyne Signs Exclusive $7m Manufacturing and Supply Agreement
- BLS appointed as exclusive manufacturer of NectarTek products for Australia, UK, and Germany
- Agreement includes volume commitments expected to generate at least $7 million in revenue for BXN in FY2026
- NectarTek is a well-established Australian healthcare company operating clinics and distributing alternative medicines
Bioxyne Limited (ASX:BXN), an Australian pharmaceutical and consumer health products company and parent company of Breathe Life Sciences (BLS), has announced a formalized manufacturing and supply agreement with its existing customer, NectarTek Australia Pty Ltd. Under the agreement, based on committed volumes, BLS expects to generate at least $7 million in sales from NectarTek in FY2026. The contract includes minimum order volumes of $3.6 million for pastilles, $2.5 million for packed flower products, $0.5 million for vapes, and $0.5 million for oral mucosal oils and other products. NectarTek has committed to ordering these quantities from 1 July 2025 to 30 June 2026. The agreement may be terminated with six months' written notice. The contract's minimum order value of approximately $7 million represents a 200% increase over historical orders from NectarTek. Actual order volumes for FY2026 may exceed these minimum commitments. Bioxyne continues to strengthen its position as the leading manufacturer and supplier of alternative pharmaceuticals, including cannabis products for authorized prescribers and clinical trials in domestic and international markets. The Company anticipates securing additional long-term contracts following a substantial increase in manufacturing capacity across all product categories with the potential to generate revenue of over $100 million per year.
Based on the committed volumes, BLS expects to generate at least $7 million in sales from NectarTek in FY2026.
Bioxyne continues to strengthen its position as the leading manufacturer and supplier of alternative pharmaceuticals, including cannabis products for authorized prescribers and clinical trials in domestic and international markets. The Company anticipates securing additional long-term contracts following a substantial increase in manufacturing capacity across all product categories with the potential to generate revenue of over $100 million per year.